These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Author: Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F, Feugier P.
    Journal: Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386.
    Abstract:
    In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). Complete resolution of aGVHD was achieved in 68.8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4-year event-free survival (EFS) was 54.6%. Grade > or =III aGVHD, > or =2 involved organs at baseline and patient age >18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.
    [Abstract] [Full Text] [Related] [New Search]